normal colorectal tissues
OtherThe investigators will extract total protein, DNA and RNA from these groups.
Other names: primary colorectal carcinoma tissues, liver metastasis tissues
NCT Number: NCT02917707
The investigators will perform integrative analysis of CRC liver metastasis
Interested in participating?
Request Info18 year–75 year
All sexes
Observational
Ganzhou City People's Hospital, Ganzhou, Jiangxi, China
The investigators will analyzed proteomes of paired normal colorectal tissues and colorectal cancer (CRC) with or without liver metastasis, sequenced transcriptomes, performed whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal colorectal tissue, primary colorectal carcinoma, and its synchronous matched liver metastasis, as well as analyzed genomics of CRC characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The investigators will extract total protein, DNA and RNA from these groups.
Other names: primary colorectal carcinoma tissues, liver metastasis tissues
Time frame: 5 years
Time frame: 5 years
Contact information is provided by the study sponsor or research team.
Da Fu
Other
Acronym: CRC-LM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04499365
Metastasis, Neoplasm Metastasis
Fuzhou, Fujian, China
View Trial DetailsNCT06863272
Castration-Resistant Prostatic Cancer, Genital Diseases
Los Angeles, California, United States
View Trial DetailsNCT06712745
Bronchial Neoplasms, Cancer, Lung
Dallas, Texas, United States
View Trial DetailsNCT06362369
ALK Genomic Tumor Aberrations, Adenocarcinoma
Aurora, Colorado, United States
View Trial Details